ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.88
-0.33%
US Tech 100
19,006.65
0.52%
S&P 500
5,587.73
-0.48%
US Dollar vs CAD
1.44601
0.20%
Bitcoin
82,459.04
5.06%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AnaptysBio Inc (ANAB) Share Price

AnaptysBio Inc

AnaptysBio Inc (ANAB)

NASDAQ
17.04
0.31
( 1.85% )
Updated: 13:23:00
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
17.04
Bid
16.99
Ask
17.07
Volume
358,836
16.4105 Day's Range 17.15
12.21 52 Week Range 41.3083
Market Cap
522.562M
Previous Close
16.73
Open
16.77
Last Trade
10
@
17.0154
Last Trade Time
13:23:27
Financial Volume
US$ 6,015,411
VWAP
16.7637
Average Volume (3m)
959,640
Shares Outstanding
30,666,781
Dividend Yield
-
PE Ratio
-3.15
Earnings Per Share (EPS)
-5.34
Revenue
17.16M
Net Profit
-163.62M

About AnaptysBio Inc

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.anaptysbio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
AnaptysBio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANAB. The last closing price for AnaptysBio was US$16.73. Over the last year, AnaptysBio shares have traded in a share price range of US$ 12.21 to US$ 41.3083.

AnaptysBio currently has 30,666,781 shares outstanding. The market capitalization of AnaptysBio is US$513.06 million. AnaptysBio has a price to earnings ratio (PE ratio) of -3.15.

Ask ADVFN Intelligence (AI)

AnaptysBio (ANAB) Options Flow Summary

ANAB Options Flow

Overall Flow

Bearish

Net Premium

-26k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

ANAB Latest News

More News

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
March 07 2025
ANAB (1.85%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
February 27 2025
ANAB (1.85%)

Form 8-K - Current report
Edgar (US Regulatory)
February 27 2025
ANAB (1.85%)

Form 8-K - Current report
Edgar (US Regulatory)
February 19 2025
ANAB (1.85%)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
February 18 2025
ANAB (1.85%)

Form 8-K - Current report
Edgar (US Regulatory)
February 12 2025
ANAB (1.85%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.618.005540166214.4417.20513.9967627516.26305141CS
44.0531.177829099312.9921.5712.21150406316.96634224CS
120.553.3353547604616.4921.5712.2195964016.24399258CS
26-17.75-51.020408163334.7940.712.2170695119.74101239CS
52-7.91-31.703406813624.9541.308312.2153109522.20903387CS
156-11.97-41.261633919329.0141.308312.2135044722.29694382CS
2601.076.7000626174115.9741.308312.0633029622.51796626CS

ANAB - Frequently Asked Questions (FAQ)

What is the current AnaptysBio share price?
The current share price of AnaptysBio is US$ 17.04
How many AnaptysBio shares are in issue?
AnaptysBio has 30,666,781 shares in issue
What is the market cap of AnaptysBio?
The market capitalisation of AnaptysBio is USD 513.06M
What is the 1 year trading range for AnaptysBio share price?
AnaptysBio has traded in the range of US$ 12.21 to US$ 41.3083 during the past year
What is the PE ratio of AnaptysBio?
The price to earnings ratio of AnaptysBio is -3.15
What is the cash to sales ratio of AnaptysBio?
The cash to sales ratio of AnaptysBio is 30.06
What is the reporting currency for AnaptysBio?
AnaptysBio reports financial results in USD
What is the latest annual turnover for AnaptysBio?
The latest annual turnover of AnaptysBio is USD 17.16M
What is the latest annual profit for AnaptysBio?
The latest annual profit of AnaptysBio is USD -163.62M
What is the registered address of AnaptysBio?
The registered address for AnaptysBio is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the AnaptysBio website address?
The website address for AnaptysBio is www.anaptysbio.com
Which industry sector does AnaptysBio operate in?
AnaptysBio operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RAYRaytech Holding Ltd
US$ 1.95
(124.14%)
89.5M
SYRSSyros Pharmaceuticals Inc
US$ 0.1658
(81.00%)
649.84M
TSVT2seventy bio Inc
US$ 4.945
(76.61%)
28.77M
HSAIHesai Group
US$ 23.60
(47.41%)
22.3M
TNONTenon Medical Inc
US$ 1.805
(44.40%)
31.59M
WCTWellchange Holdings Company Limited
US$ 0.69
(-72.51%)
28.83M
ARVNArvinas Inc
US$ 8.4555
(-51.85%)
13.56M
LZMHLZ Technology Holdings Ltd
US$ 9.2141
(-41.16%)
487.33k
SPGCSacks Parente Golf Inc
US$ 0.10395
(-35.07%)
31.74M
KBSXFST Corporation
US$ 3.84
(-27.55%)
49.47k
SYRSSyros Pharmaceuticals Inc
US$ 0.1659
(81.11%)
656.69M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0394
(17.61%)
386.14M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 8.08
(9.49%)
250.68M
NVDANVIDIA Corporation
US$ 110.14
(2.95%)
248.12M
CUTRCutera Inc
US$ 0.109
(-15.18%)
209.36M

ANAB Discussion

View Posts
tw0122 tw0122 4 weeks ago
ANAB $16.49 + 33% ...  will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT....
👍️ 1
Monksdream Monksdream 6 months ago
ANAB definite uptrend
👍️0
gfp927z gfp927z 3 years ago
HighPeaks, The NY Times article was high profile, but the connection to ANAB isn't readily apparent.

Even with the partial sale/monetization of the revenue stream from dostarlimab in December, the drug is also being studied by Glaxo for other cancer types (endometrial, non-small cell lung, ovarian, and mismatch repair deficient solid tumors). One question to answer is whether the monetization deal with Sagard was only for colorectal, or for all the indications? Probably for all, but I'll have to do more research.

ANAB has numerous other programs and a large pile of cash, so looks interesting. But investing in biotech requires a ton of research, but even then you still don't know what you have, and landmines are everywhere. Better to invest in 'what you know', as Buffett recommends :o)




---
👍️0
HighPeaks HighPeaks 3 years ago
Thanks TP. Yeah this has the potential to really be a big mover. So surprised no one has made the connection between this potential miracle drug and $ANAB receiving royalties on it(as it’s originator). GSK is the collaborator who has just commercialized it but it’s ANAB invention.
👍️0
tedpeele tedpeele 3 years ago
Tremendous find HighPeaks. .You have been early on quite a few big movers. I'm thinking this is yet another one.

Will be watching this closely...thanks.
👍️0
HighPeaks HighPeaks 3 years ago
According to this link ANAB gets 8-25% royalties from Dostarlimab. This drug has recently shown phenomenal results in a trial at Memorial Sloan Kettering Hospital. All patients fully recovered from rectal cancer.
https://www.globenewswire.com/fr/news-release/2020/10/26/2114250/0/en/AnaptysBio-and-GlaxoSmithKline-Amend-Strategic-Immuno-Oncology-Collaboration.html
👍️0
TFMG TFMG 5 years ago

$ANAB | #Anaptysbio Spikes After Drug Designation


Nice spike in the afterhours session, lets hope we
can get some continuation tomorrow.
Target $29.00 to Fib Golden Pocket
Also a very large gap to fill at $35.00
AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis
PLEASE GIVE US A LIKE IF YOU FIND OUR CONTENT HELPFUL, THANK YOU.


👍️0
LoveItInBishop LoveItInBishop 5 years ago
RSI @ 16. laughable. Zacks has positive take. https://finance.yahoo.com/news/anaptysbio-enters-oversold-territory-135501475.html
👍️0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $ANAB Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

👍️0
waterchaser waterchaser 5 years ago
LOL! Twitter PnD. Buyer beware.
👍️0
420man 420man 5 years ago
Once the real bounce starts it will be fast....
👍️0
Crazy Money Crazy Money 5 years ago
$10 to da moon
👍️0
420man 420man 5 years ago
This will bounce..... 15 AH
👍️0
RJ Trotts RJ Trotts 5 years ago
trying to bounce back over $11, hoping for more
👍️0
TaxiCaT TaxiCaT 5 years ago
Ouch -
👍️0
celle celle 6 years ago
Nothing happen here?
👍️0
manny371 manny371 7 years ago
This stock is making noise! Bought in Sept $ANAB
👍️0

Your Recent History

NASDAQ
ANAB
AnaptysBio
EU
CTAC
Ctac NV
LSE
OVG
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads